Thus, such individuals can suffer the serious and debilitating consequences of the disease which include peripheral nerve damage, damage to the retinas of the eyes, kidney problems and cardiac damage. Oath vous présentera également des publicités personnalisées sur les produits de ses partenaires. The same is true for a Phase 1 trial to control the unbearable pain from advanced pancreatic cancer. Mind you I did not bet the farm, but I thought it warranted a position which has now paid off well. Analyst Certification I, Robert Goldman, hereby certify that the view expressed in this research report or article, accurately reflect my personal views about the subject securities and issuers. Daniel Van Hoff, is arguably the leading authority on pancreatic cancer.
At least Goldman notes what he is compensated by a third party in his articles. Insofar as money to complete the task is concerned, there is further dilution which the market can bare for this product if it works. Nor shall it create any principal-agent relationship between the reader and us. I am glad I did my own due diligence as my investment from last year is up nearly 400%. Where are they even getting any funds to do anything? This is a delivery system and not a drug. In all instances, the Reader should conduct further inquiry into the Profiled Company and its securities.
Constitution, and are provided solely for the general opinionated discussion of our readers. Importantly, significantly greater degrees of tumor shrinkage were observed in those dogs treated with encapsulated cells in combination with cyclophosphamide versus those dogs receiving cyclophosphamide alone. The American Cancer Society highlights the most common approaches in practice and under development, today. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. PharmaCyte Biotech believes that cannabinoids or cannabinoid-like compounds may be used in combination with the Cell-in-a-Box® technology as cancer treatments in much the same way that the Cell-in-a-Box® plus ifosfamide combination will be used to treat pancreatic cancer.
Orphan drug designation in the U. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. Both cancer and diabetes are multi-billion dollar industries. Investors Hub iHub - Android Apps on Google Play Mar 28, 2017 · Stock message boards, quotes, charts,. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. No mention of that here. He recently brought abraxane to market for celgene….
When investing in disruptive technologies, it is important to be able to identify investments you should not invest in along with those that may show promise. He has also served as Professor of Molecular Gastroenterology at the University of Heidelberg and Head of a division at the German Cancer Research Center. Plus, we believe management does indeed have access to the capital necessary to conduct near term trials because of these strengths. Members are forbidden from sharing or reposting any ValueForum. PharmaCyte Biotech's Cell-in-a-Box represents a potential opportunity for an implanted cellulose-based capsule filled with live cells capable of producing insulin, to mirror the activity of a normal pancreas and make, store and deliver the proper dosages of insulin into the blood stream, thereby controlling blood sugar levels. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then as it grew, I also took my money out, letting the rest ride.
The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, and transport living cells. Any trade entered into risks the possibility of losing the funds invested. Ironically, the stock is trading near year lows despite its plethora of good news and multiple trials in the offing near term which only enhance valuations. Garret Yount, both of whom will play major roles in the development of cannabinoid-based disease treatments. PharmaCyte Biotech's cell therapy has just been granted Orphan Drug status by the U. So far, from only part of the due diligence I just mentioned, things may look good.
The White House push on taking the mortgage giants out of conservatorship is expected to intensify upon the expected Senate confirmation of Mark Calabria to lead the Federal Housing Finance Agency. All stock board posts are the opinion of. Interestingly, articles that are positive, or where it is so blindingly obvious that something is wrong with the company, generate few, or no comments… If someone raises a red flag you can either heed the call, or ignore it. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. In the case of a dog diagnosed with two tumors, the tumor that did not receive encapsulated cells but received cyclophosphamide alone was reduced by only 14% while the tumor receiving encapsulated cells plus cyclophosphamide showed a 70% reduction in tumor volume. . Just my opinion after having done complete due diligence for going on two years.
In 2014, the Company also acquired an exclusive, worldwide license to use that same technology in combination with compounds from constituents of Cannabis for the development of disease treatments. Separately, we anticipate meaningful progress on the diabetes and cannabis fronts in the second half of this year as well. How about University of technology in Sydney having a partnership to study diabetes using melligen cells and cell in box? We really like the chart as well! There is no doubts that the company will continue to dilute shareholders. It is a high-risk stock for sure, and under some selling pressure. These milestones include mid-stage and preclinical studies for the treatment of pancreatic cancer and its serious and debilitating symptoms, and for diabetes.